Drug
Neratinib clinical trials
Also written Nerlynx and HKI-272.
- studies test it
- 67
- open now
- 15
- in phase 3
- 4
- first study started
- 2003
Keep track of what changes. Save the neratinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
66 studies that test it; most in 2009 (9); 1 more planned to start later
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 6 |
| 2009 | 9 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 34
- Phase 2
- 39
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 32 · Other 35
Puma Biotechnology, Inc. (30) · NSABP Foundation Inc (4) · Virginia Commonwealth University (2) · Memorial Sloan Kettering Cancer Center (2) · Convalife (Shanghai) Co., Ltd. (2) · National Cancer Institute (NCI) (2) · University Health Network, Toronto (2) · H. Lee Moffitt Cancer Center and Research Institute (1)
Often tested with
Tested in the same studies.
Trastuzumab (8) · Paclitaxel (6) · Capecitabine (5) · Abemaciclib (4) · Ado-Trastuzumab Emtansine (3) · Fulvestrant (3) · Olaparib (3) · Pembrolizumab (2)
Studies
Open first, then newest update. How each study uses neratinib is read from its arms, and is right about nine times in ten.
Testing it · 67
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Neratinib Maleate
- Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual DiseaseRecruitingPhase 2University Health Network, TorontoNCT05388149Written as Neratinib
- Neratinib in Combination With Ruxolitinib in Patients With mTNBCRecruitingEarly Phase 1Baylor Research InstituteNCT06008275Written as Neratinib Oral Tablet
- Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 GeneRecruitingPhase 1National Cancer Institute (NCI)NCT05372614Written as Neratinib Maleate
- T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain MetastasisRecruitingPhase 2Fudan UniversityNCT07152782Written as Neratinib
- Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast CancersRecruitingPhase 2Ruth O'ReganNCT04886531Written as Neratinib
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)RecruitingPhase 2Scott R. Plotkin, MD, PhDNCT04374305Written as Neratinib
- INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)RecruitingPhase 2David Reardon, MDNCT02977780Written as Neratinib
- Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerNot yet recruitingPhase 2University of California, San DiegoNCT07729046Written as Neratinib + endocrine therapy
- Using Tumor Models to Determine TreatmentsRecruitingPhase 2University Health Network, TorontoNCT06813079Written as Neratinib
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingPhase 3UNICANCERNCT05615818Written as Neratinib
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorRecruitingPhase 2Dartmouth-Hitchcock Medical CenterNCT05933395Written as Neratinib
- Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus PertuzumabRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05760612Written as Trastuzumab and neratinib
- Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 MutationsNot yet recruitingPhase 2Convalife (Shanghai) Co., Ltd.NCT06519110Written as Neratinib tablets
- Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR MutationsNot yet recruitingPhase 2Convalife (Shanghai) Co., Ltd.NCT06029816Written as Neratinib tablets
- Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated CaSuspendedPhase 1/2Virginia Commonwealth UniversityNCT03919292Written as Neratinib
- Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast CancerCompletedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT03377387Written as Neratinib
- Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal CancerActive, not recruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06109467Written as Neratinib
- Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian CancerActive, not recruitingPhase 1Virginia Commonwealth UniversityNCT04502602Written as Neratinib 160 mg
- HKI-272 for HER2-Positive Breast Cancer and Brain MetastasesCompletedPhase 2Dana-Farber Cancer InstituteNCT01494662Written as HKI-272
See all 67 studies that test neratinib →
Given in every arm · 12 — neratinib is usual care beside what is tested
- Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06126276Written as Neratinib Maleate
- Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast CancersRecruitingPhase 2Vanderbilt-Ingram Cancer CenterNCT05919108Written as Neratinib
- Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationTerminatedPhase 1M.D. Anderson Cancer CenterNCT03065387Written as Neratinib
- Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast CancerTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT03101748Written as Neratinib
- Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast CancerTerminatedPhase 2Dana-Farber Cancer InstituteNCT03289039Written as Neratinib
- Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and NeratinibCompletedPhase 2University of California, San FranciscoNCT03094052Written as Neratinib
- Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant NeratinibActive, not recruitingPhase 2Spanish Breast Cancer Research GroupNCT05252988Written as Neratinib
- Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsTerminatedPhase 2Puma Biotechnology, Inc.NCT01953926Written as Neratinib
- An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and LoperamideCompletedPhase 2Puma Biotechnology, Inc.NCT02400476Written as Neratinib
- Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast CancerCompletedPhase 2Washington University School of MedicineNCT01670877Written as Neratinib
- Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 StatusStatus unknownPhase 2NSABP Foundation IncNCT03457896Written as Neratinib
- Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung CancerCompletedPhase 2Puma Biotechnology, Inc.NCT01827267Written as neratinib
As the comparator · 1 — what is tested is compared with neratinib
Codes
What other systems call neratinib · ClinicalTrials.gg INT004670
- MeSH (NLM) C487932neratinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) JJH94R3PWBNERATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1940643Confirmed FDA, Wikidata
- Wikidata Q6995920neratinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C49094NeratinibConfirmed FDA, Wikidata
- DrugBank DB11828One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C487932 | neratinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | JJH94R3PWB | NERATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1940643 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6995920 | neratinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C49094 | Neratinib | Confirmed FDA, Wikidata |
| DrugBank | DB11828 | — | One source Wikidata |
Also registered as neratinib maleate anhydrous (UNII 9RM7XY23ZS · RxNorm 1940642).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.